Bone Reconstruction Using Patients Own Bone Marrow Stem Cells to Treat Early Avascular Necrosis of the Femur Head

What this Trial Is About

Researchers are evaluating the use of tissue-engineered bone made from commercial decalcified bone scaffolds combined with a patients own bone marrow mesenchymal stem cells to treat early non-traumatic avascular necrosis of the femoral head. This condition progresses quickly, often leading to femoral head collapse within 1 to 4 years. Early intervention aims to preserve the femoral head and improve outcomes compared to current treatments like core decompression and bone grafting, which have limitations including donor site damage and limited biological activity. The study uses tissue engineering to create a composite of seed cells, growth factors, and scaffold materials that are transplanted to the bone defect site. This method provides structural support and promotes bone and blood vessel regeneration. The intervention involves using tissue-engineered bone with autologous bone marrow mesenchymal stem cells for femoral head repair. The treatment is applied during surgery, and the study will monitor its effects over time to assess clinical benefits and safety. Participants will be assessed before surgery and followed up at multiple time points including 1 month, 2 months, 3 months, 6 months, and one year after the operation. Evaluations will include effectiveness measures of the tissue-engineered bone in treating femoral head necrosis and safety monitoring. The study involves clinical examinations, imaging, and other tests to track bone repair and function. The total participation duration for each patient spans at least one year after surgery to observe long-term outcomes.

Clinical Transformation of Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Avascular Necrosis of Femur Head